Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Current Assets (2019 - 2025)

Harmony Biosciences Holdings' Current Assets history spans 7 years, with the latest figure at $907.0 million for Q4 2025.

  • For Q4 2025, Current Assets rose 56.58% year-over-year to $907.0 million; the TTM value through Dec 2025 reached $907.0 million, up 56.58%, while the annual FY2025 figure was $907.0 million, 56.58% up from the prior year.
  • Current Assets for Q4 2025 was $907.0 million at Harmony Biosciences Holdings, up from $838.8 million in the prior quarter.
  • Across five years, Current Assets topped out at $907.0 million in Q4 2025 and bottomed at $177.7 million in Q1 2021.
  • The 5-year median for Current Assets is $453.4 million (2023), against an average of $460.0 million.
  • The largest annual shift saw Current Assets fell 3.82% in 2021 before it surged 60.57% in 2025.
  • A 5-year view of Current Assets shows it stood at $284.4 million in 2021, then surged by 40.73% to $400.3 million in 2022, then grew by 12.69% to $451.1 million in 2023, then increased by 28.42% to $579.3 million in 2024, then soared by 56.58% to $907.0 million in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Current Assets are $907.0 million (Q4 2025), $838.8 million (Q3 2025), and $691.4 million (Q2 2025).